Sleep Thermography for Diagnosis of Obstructive Sleep Apnea (TERMOAPNEA)

Sponsor
Hospital Universitario Araba (Other)
Overall Status
Recruiting
CT.gov ID
NCT04206449
Collaborator
Ibermática/i3B (Other), Instituto de Salud Carlos III (Other), Bioraba (Other)
198
1
2
59.7
3.3

Study Details

Study Description

Brief Summary

To assess the diagnostic validity and cost-effectiveness of an infrared thermography system in adults with clinical suspicion of Obstructive Sleep Apnea (OSA).

Condition or Disease Intervention/Treatment Phase
  • Other: Therapeutic decision PSG
  • Other: Therapeutic decision Infrared thermgraphy system
N/A

Detailed Description

AIMS: To assess the diagnostic validity and cost-effectiveness of an infrared thermography system, integrated in an expert diagnostic algorithm (TIS), to determine the sleep stages and identify respiratory events, compared to conventional polysomnography (PSG) in adults with clinical suspicion of Obstructive Sleep Apnea (OSA).

METODOLOGY: DESIGN: Prospective, unicentric, randomized and blinded study carried out into two phases: Phase I: Development of the tool in 99 full valuable adults with suspected OSA (PSG recruitment, coordination and quality control, image capture, Information and development of the expert system); Phase II: Validation of the tool compared with the PSG in another group of 99 full valuable adults with suspected OSA. INSTRUMENTALIZATION: a) Clinical history and anthropometric variables; b) Sleep and quality of life questionnaires; c) PSG; d) TIS; e) Cost-effectiveness study.

ANALYSYS : The validity of the results of the TIS will be analyzed compared with the results of the PSG. The agreement measure will be established according to the different categories of the Apnea-Hypopnea Index (AHI), using ROC (Receiver Operating Characteristic) curves and the area under the curve. The investigators will also validate the therapeutic decisions made with PSG compared to those performed with the TIS. Finally, a cost-effectiveness study will be performed.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
198 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Diagnostic
Official Title:
Sleep Thermography for Diagnosis of Obstructive Sleep Apnea (OSA)
Actual Study Start Date :
Sep 10, 2018
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Sep 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Infrared thermography system

Therapeutic decision taken with infrared thermography system, integrated in an expert diagnostic algorithm (TIS), to determine the sleep stages and Apnea-Hypopnea Index (AHI).

Other: Therapeutic decision Infrared thermgraphy system
Also randomizing for Infrared thermography system

Active Comparator: Standard Polysomnography (PSG)

Therapeutic decision taken with Standard Polysomnography (PSG), to determine the sleep stages and Apnea-Hypopnea Index (AHI)

Other: Therapeutic decision PSG
Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)

Outcome Measures

Primary Outcome Measures

  1. Apnea-Hypopnea Index (AHI) [Baseline]

    Count the respiratory events (apneas and hypopneas) that occur during sleep using a high sensitivity infrared thermal camera integrated in an expert diagnostic algorithm (TIS).

Secondary Outcome Measures

  1. Validation of the therapeutic decision [6 month]

    Analyze the concordance in the therapeutic decision using clinical findings and the results of Apnea-Hypopnea Index (AHI) from standard polysomnography (PSG) compared with data from infrared thermography system. In the Phase II.

  2. Cost effectiveness analysis [6 month]

    Cost-efficacy evaluation: the analysis will be made in both arms based on intention to treat. Only direct costs will be analyzed: the cost of the use of polysomnography and infrared thermography system (Staff and consumable material).

  3. Epworth Sleepiness Scale [baseline and at 6 month]

    The Epworth Sleepiness Scale (the sum of 8 items score,0-3) can range from 0 to 24. Scores of 11-24 represent increasing levels of excessive daytime sleepiness.

  4. STOP-Bang Questionnaire [baseline and at 6 month]

    The questionnaire screens for obstructive sleep apnea (OSA): Low risk of OSA: <3 High risk of OSA: ≥3

  5. Berlin questionnaire [baseline and at 6 month]

    The questionnaire consists of 3 categories related to the risk of having sleep apnea. Patients can be classified into High Risk or Low Risk based on their responses to the individual items and their overall scores in the symptom categories. High Risk: if there are 2 or more categories where the score is positive. Low Risk: if there is only 1 or no categories where the score is positive. Scoring Categories: Category 1 is positive with 2 or more positive responses to questions 2-6 Category 2 is positive with 2 or more positive responses to questions 7-9 Category 3 is positive with 1 positive response and a BMI>30

  6. Blood pressure [baseline and at 6 month]

    Blood pressure measurements: systolic blood pressure and diastolic blood pressure

  7. Anthropometric variables (Body mass index) [baseline and at 6 month]

    Body mass index

  8. Quality of life (EuroQOL test) [baseline and at 6 month]

    Evaluate by EuroQOL test, is a standardised measure of health status. Description of the state of health in five dimensions (mobility, self-car, usual activities, pain/discomfort and anxiety/depression), each o wich is defined with three levels of severity, as measured by a Likert scale type (no problems, some problems and many problems or inability to activity).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Men and women over 18 years to 75 years old, with clinical suspicion of OSA

  • Written informed consent signed

Exclusion Criteria:
  • Place of residence more than 100 km from the hospital

  • Severe, unstable or exacerbated cardio-vascular, cerebro-vascular or respiratory disease, that makes it impossible to carry out adequate studies

  • Presence of insomnia, depressive syndrome or epilepsia

  • Patients diagnosed of any acute inflammatory episode of the cranium-maxillo-facial area or any systemic infection that develops with fever> 38 ºC at the time of testing

  • Patient with malformation syndromes, Down syndrome and neuromuscular diseases

  • Patient on active treatment with Positive continuous pressure (CPAP )

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Universitario Araba Gasteiz / Vitoria Araba Spain 01009

Sponsors and Collaborators

  • Hospital Universitario Araba
  • Ibermática/i3B
  • Instituto de Salud Carlos III
  • Bioraba

Investigators

  • Study Director: Joaquin Duran-Cantolla, MD, Hospital Universitario Araba

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Joaquin Duran-Cantolla, MD, Principal Investigator, MD, PhD, Hospital Universitario Araba
ClinicalTrials.gov Identifier:
NCT04206449
Other Study ID Numbers:
  • PI17/02011
First Posted:
Dec 20, 2019
Last Update Posted:
Sep 17, 2021
Last Verified:
Sep 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Joaquin Duran-Cantolla, MD, Principal Investigator, MD, PhD, Hospital Universitario Araba
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 17, 2021